Literature DB >> 30249100

AJCC 8th Edition (2017) versus AJCC 7th Edition (2010) in thin melanoma staging.

L Roncati1, F Piscioli2.   

Abstract

In comparison with the 7th Edition, the 8th Edition of the American Joint Committee on Cancer (AJCC) staging system no longer considers the mitotic count in the a or b T1 categorization for melanoma, but it adopts a sub-stratification based on the Breslow's depth. Today, the death burden of thin melanoma is still severe, despite of attempts for early screening. We believe that a bio-histological implementation may explain this evidence. It is generally accepted that melanoma progression includes two subsequent phases: the radial growth phases (RGP) and the vertical growth phase (VGP). If left untreated, RGP is able to move towards VGP. In this second phase, melanoma grows as a malignant, mitotically active, tumor with invasive and metastatic capacities. By our experience, thin melanoma includes three bio-histological subtypes: the non-tumorigenic micro-invasive RGP without significant regression, the micro-invasive RGP with regression of uncertain tumorigenic potential at diagnosis, due to the extensive presence (> 75%) of regression which could contain a VGP clone, and the micro-invasive tumorigenic VGP. Therefore, we are prone to support that the prognosis of thin melanoma is correlated with the type of growth phase inside it.

Entities:  

Mesh:

Year:  2018        PMID: 30249100     DOI: 10.4149/neo_2018_170701N452

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  2 in total

1.  Tspan8 Drives Melanoma Dermal Invasion by Promoting ProMMP-9 Activation and Basement Membrane Proteolysis in a Keratinocyte-Dependent Manner.

Authors:  Manale El Kharbili; Muriel Cario; Nicolas Béchetoille; Catherine Pain; Claude Boucheix; Françoise Degoul; Ingrid Masse; Odile Berthier-Vergnes
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

Review 2.  Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician.

Authors:  Rebecca Adams; Bernhard Moser; Sophia N Karagiannis; Katie E Lacy
Journal:  Cancers (Basel)       Date:  2021-11-10       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.